The global infectious disease diagnostics market by Product Type (Kits & Reagents, and Instruments), By Disease Type (HIV, Hepatitis, Healthcare Associated Infections (HAIs), Human Papillomavirus (HPV), Tuberculosis (TB), Influenza, and Others), By Technology (Immunodiagnostics, Polymerase Chain Reaction, Next Generation Sequencing, and Others), By Test Location (Laboratory Testing, Point of Care Testing), By End User (Hospitals, Pathology/Diagnostic Laboratories, Research Institutes, Home-Care Settings, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 15,112.2 million in 2017, and is projected to exhibit a CAGR of 6.1% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights. Availability of wide number of diagnostic tests, increasing need for diagnosis of infectious diseases, and high prevalence of infectious diseases is expected to fuel growth of the infectious disease diagnostics market.
Cepheid received the U.S. Food & Drug Administration clearance to market Xpert Xpress Strep A test in October 2017, which provides rapid, accurate, and reliable molecular detection of Streptococcus pyogenes. BioMérieux launched Lyme Disease Diagnostic Test in the U.S. in 2015. BioMérieux’s VIDAS Lyme IgG and VIDAS Lyme IgM II assays provide rapid and differential detection of Lyme disease infection.
Bio-Rad Laboratories, Inc. introduced BioPlex 2200 Syphilis Total & RPR Assay, a novel Syphilis Testing Method in 2017. Moreover, Bio-Rad Laboratories, Inc. launched Amplichek STI, a molecular infectious disease quality control product for monitoring the performance of in-vitro laboratory nucleic acid testing procedure for detection of sexually transmitted infections in 2017.
Roche Diagnostics launched a HIV test in the U.S., Elecsys HIV combi PT assay in 2017. This test is capable of detecting the virus about two weeks earlier and can diagnose multiple infectious diseases. Moreover, Roche launched cobas TV/MG in January 2018, for use on the cobas 6800/8800 systems for direct detection of Trichomonas vaginalis (TV) and/or Mycoplasma genitalium (MG) DNA in both symptomatic and asymptomatic individuals.
Browse 44 Market Data Tables and 50 Figures spread through 171 Pages and in-depth TOC on Infectious Disease Diagnostics Market by Product Type (Kits & Reagents, and Instruments), By Disease Type (HIV, Hepatitis, Healthcare Associated Infections (HAIs), Human Papillomavirus (HPV), Tuberculosis (TB), Influenza, and Others), By Technology (Immunodiagnostics, Polymerase Chain Reaction, Next Generation Sequencing, and Others), By Test Location (Laboratory Testing, Point of Care Testing), By End User (Hospitals, Pathology/Diagnostic Laboratories, Research Institutes, Home-Care Settings, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026
To know the latest trends and insights prevalent in the Infectious Disease Diagnostics Market, click the link below:
Initiatives and funding from individual organizations to promote research and development of effective diagnostic tests for infectious diseases is expected to boost growth of the infectious disease diagnostics market. For instance, QuantuMDx Group received funding from Bill & Melinda Gates Foundation to develop and test company’s CAPTURE-XT pathogen concentration technology and Q-POC molecular diagnostic platform for rapid low cost detection of tuberculosis in 2016.
In January 2018, University of Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases, and point-of-care testing in remote locations to help enable rapid diagnosis, and rapid treatment. The Foundation for Innovative New Diagnostics (FIND) announced release of a new strategy in January 2018, which focuses on combatting antimicrobial resistance (AMR) by accelerating the use of diagnostics.
FIND announced new collaboration agreements in January 2018, with Becton, Dickinson, and Company (BD), Fondation Botner, the Global Antibiotic Research & Development Partnership (GARDP), the Drugs for Neglected Diseases Initiative (DNDi), and the South African Medical Research Council (SAMRC) that will commence in 2018, to address AMR and other diagnostic challenges in emerging economies.
Key Takeaways of the Infectious Disease Diagnostics Market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.